摘要
OBJECTIVE:To evaluate the add-on effect of Qinbei Qingfei Yiqi(QBQFYQ) granules for ventilator-associated pneumonia(VAP) in non-infectious critically ill patients.METHODS:In this randomized controlled trial, 80non-infectious critically ill patients undergoing mechanical ventilation in the intensive care unit(ICU)were randomly divided into two groups:those receiving QBQFYQ granules plus usual treatment(experimental group, n = 50) and those receiving only the usual treatment(control group, n = 30).The main outcome measures were VAP rate, time of VAP occurrence, duration of mechanical ventilation,and length of ICU stay.Interleukin-6(IL-6), C-reactive protein(CRP), and T-lymphocyte(CD4+, CD8+,and CD4+/CD8+ ratio) serum levels were also evaluated before and after treatment.RESULTS:Compared with the control group treatment, QBQFYQ administration significantly reduced the duration of mechanical ventilation [(9.58± 3.14) vs(12.52 ± 4.33) days] and length of ICU stay [(14.57 ± 3.72) vs(17.82 ± 5.24) days] and delayed VAP occurrence [(4.31 ± 0.86) vs(2.43 ± 0.27)days].Additionally, CRP and IL-6 serum levels and CD4+/CD8+ ratio were significantly lower in the experimental group(P < 0.05) than in the control group.However, there were no significant differences in hospital mortality rate(30.0% vs 33.3%) and adverse events(4.0% vs 6.7%).CONCLUSION:QBQFYQ delays the time of VAP occurrence and shortens the duration of mechanical ventilation in non-infectious critically ill patients,possibly through anti-inflammatory and immunomodulatory mechanisms.
OBJECTIVE：To evaluate the add-on effect of Qinbei Qingfei Yiqi（QBQFYQ） granules for ventilator-associated pneumonia（VAP） in non-infectious critically ill patients.METHODS：In this randomized controlled trial, 80non-infectious critically ill patients undergoing mechanical ventilation in the intensive care unit（ICU）were randomly divided into two groups：those receiving QBQFYQ granules plus usual treatment（experimental group, n = 50） and those receiving only the usual treatment（control group, n = 30）.The main outcome measures were VAP rate, time of VAP occurrence, duration of mechanical ventilation,and length of ICU stay.Interleukin-6（IL-6）, C-reactive protein（CRP）, and T-lymphocyte（CD4＋, CD8＋,and CD4＋/CD8＋ ratio） serum levels were also evaluated before and after treatment.RESULTS：Compared with the control group treatment, QBQFYQ administration significantly reduced the duration of mechanical ventilation [（9.58± 3.14） vs（12.52 ± 4.33） days] and length of ICU stay [（14.57 ± 3.72） vs（17.82 ± 5.24） days] and delayed VAP occurrence [（4.31 ± 0.86） vs（2.43 ± 0.27）days].Additionally, CRP and IL-6 serum levels and CD4^＋/CD8^＋ ratio were significantly lower in the experimental group（P 0.05） than in the control group.However, there were no significant differences in hospital mortality rate（30.0% vs 33.3%） and adverse events（4.0% vs 6.7%）.CONCLUSION：QBQFYQ delays the time of VAP occurrence and shortens the duration of mechanical ventilation in non-infectious critically ill patients,possibly through anti-inflammatory and immunomodulatory mechanisms.
基金
Supported by the Natural Science Foundation of Heilongjiang Province-Intervention of Qinbei Qingfei Yiqi granules' preparation on ventilator-associated pneumonia(No.D201125)
